Innovative angle-adaptive mechanical stabilization for large-bore catheter access CARLSBAD, CA, UNITED STATES, December 23, 2025 / EINPresswire.com / -- AVACEN , Inc., a leader in non-invasive and access-adjacent medical device innovation, today announced the issuance of a U.S. utility patent for its CATHeter STAbilization (CATHSTA™) device. CATHSTA™ is designed for high-acuity applications requiring secure large-bore vascular access, including transcatheter cardiac interventions, mechanical cir

SEONGNAM, South Korea, Dec. 23, 2025 /PRNewswire/ -- SN Bioscience Inc. (CEO Young Hwan PARK) announced that the FDA had granted Orphan Drug Designation (ODD) on December 10 for gastric cancer (including gastroesophageal junction cancer) to SNB-101 (API: SN-38) which is a polymer nanoparticle drug under phase 1b/2 clinical trial for small cell lung cancer. SNB-101 is the world's first nanoparticle anticancer drug that has formulated extremely insoluble SN-38 into polymer nanoparticles, which is

Cancer Immunotherapy, LYMPHIR™, launched in the U.S. in December 2025 Completed $36 million in strategic financings, of which $18 million was via private placement and concurrent registered direct offering on December 10, 2025, to strengthen cash position and support continued commercialization of LYMPHIR CRANFORD, N.J., Dec. 23, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq

Subsidiary, Citius Oncology, launches cancer immunotherapy, LYMPHIR™, in the U.S. in December 2025 CRANFORD, N.J., Dec. 23, 2025 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products today reported business and financial results for the fiscal year ended September 30, 2025. "2025 was a pivotal year for Citius as we successfully launched

Expands MedSurg portfolio into the fast-growing synthetic tissue matrices technology space in acute care settings in the U.S. Accelerates Solventum's business transformation through the acquisition of a strategically aligned asset in a technology adjacency ST. PAUL, Minn., Dec. 23, 2025 /PRNewswire/ -- Solventum (NYSE: SOLV) announced today it has completed the acquisition of Acera Surgical (Acera), a privately held bioscience company focused on developing and commercializing fully engineered m

This recall involves removing certain devices from where they are used or sold. The FDA has identified this recall as the most serious type. This device may cause serious injury or death if you continue to use it. Affected Product The FDA is aware that Draeger has issued a letter to affected customers recommending certain ErgoStar Catheter Mounts be removed from where they are used or sold: Part Number Designation UDI-DI MP01840 ErgoStar CM 40 04048675420736 MP01845 ErgoStar CM 45 04048675420729

This recall involves removing certain devices from where they are used or sold. The FDA has identified this recall as the most serious type. This device may cause serious injury or death if you continue to use it. Affected Product The FDA is aware that Cook Medical has issued a letter to affected customers recommending certain Zenith Alpha 2 Thoracic Endovascular Graft proximal components be removed from where they are used or sold. Product Names: Zenith Alpha 2 Thoracic Endovascular Graft, prox

EBCI helps PCNSL patients understand the results from ONO PHARMA's recent phase II PROSPECT study, which tested the safety and efficacy of tirabrutinib. REDMOND, WA, UNITED STATES, December 23, 2025 / EINPresswire.com / -- ONO PHARMA recently announced positive results from the phase II PROSPECT study, which tested the safety and efficacy of tirabrutinib is in U.S. patients with relapsed (came back after treatment) or refractory (didn’t respond to treatment) Primary Central Nervous System Lympho

CMTA announces a $100,000 investment in EverTree Bio following early CMT1A testing through the CMTA Preclinical Toolbox, supporting continued research progress. EverTree’s approach aligns with our mission to advance strong, patient-focused science that may be ignored. Our goal is to ensure programs like this are not stalled by early-stage funding gaps.” — Sue Bruhn, PhD, CMTA CEO GLENOLDEN, PA, UNITED STATES, December 23, 2025 / EINPresswire.com / -- The Charcot-Marie-Tooth Association (CMTA) an

Scientists present a new approach that could empower the immune system to combat cancer cells and pave the way for new treatments for this deadly disease. SHARJAH, EMIRATE OF SHARJAH, UNITED ARAB EMIRATES, December 23, 2025 / EINPresswire.com / -- Researchers at the University of Sharjah are exploring a promising approach that could enhance the immune system’s ability to fight cancer, potentially paving the way for new treatments. In a recent article published in the journal Cell Death & Disease